Xconomy Forum: Reinventing Biotech’s Business Model, San Francisco Style

Biotech companies used to think about how to build enduring companies with soup-to-nuts operations that had everything under one corporate flag, from research to development to manufacturing to marketing. Those models increasingly look like relics. Investors have grown weary of the long timelines, big bucks, and high risk that come with building such organizations. Stung by losses, a number of VCs, entrepreneurs and investors are turning to small core teams that lean heavily on contract firms to try to make biotech more nimble, less capital intensive, and a more attractive industry for investment. Come join Xconomy’s half-day forum for a number of case studies and interactive chats with national leaders who are looking to reinvent the biotech business model.

Confirmed Speakers

Brian Atwood
- Managing Director, Versant Ventures
Robert Blum
- CEO, Cytokinetics
Tony Coles
- CEO, Onyx Pharmaceuticals
Jens Eckstein
- President, SR One
Mark Goldsmith
- CEO, Global Blood Therapeutics; Venture Partner, Third Rock Ventures
Steve Kaldor
- CEO, Quanticel; Venture Partner, Versant Ventures
Richard Lindberg
- Executive Director, Head of the Centers for Therapeutic Innovation – California, Pfizer Inc.
Diego Miralles
- Head of West Coast research center, Janssen Labs
Mike Morrissey
- CEO, Exelixis
Clare Ozawa
- Chief Business Officer, Inception Sciences
Deepa Pakianathan
- General Partner, Delphi Ventures
James Sabry
- VP of Partnering, Genentech
Risa Stack
- Partner, Kleiner Perkins Caufield & Byers
Peter Thompson
- Venture Partner, OrbiMed Advisors
Luke Timmerman
- National Biotechnology Editor, Xconomy (moderator)